FDA Orders St. Jude To Expand Surveillance Of ICD Leads, Including Durata
This article was originally published in The Gray Sheet
Executive Summary
The agency announced Section 522 post-market surveillance orders that target St. Jude Medical’s recalled Riata leads, as well as the currently marketed Durata leads.